Skip to search formSkip to main contentSkip to account menu

esketamine

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
OBJECTIVE To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive… 
Review
2020
Review
2020
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder
ABSTRACT Introduction: In March 2019, intranasal esketamine was approved by the Food and Drug Administration (FDA) for the… 
Highly Cited
2019
Highly Cited
2019
Intranasal Esketamine (SpravatoTM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant.
Intranasal esketamine for treatment-resistant depression. 
Highly Cited
2019
Highly Cited
2019
Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study
Purpose To assess the pharmacokinetics and safety of pure S-ketamine (esketamine) in Chinese patients undergoing painless… 
Review
2019
Review
2019
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Highly Cited
2019
Highly Cited
2019
A Word to the Wise About Intranasal Esketamine.
Rarely has there been so much anticipation for a new antidepressant as has been seen for intranasal esketamine, the putatively… 
Review
2019
Review
2019
The influence of ketamine on drug discovery in depression.
Review
2018
Review
2018
Comparative study of esketamine and racemic ketamine in treatment-resistant depression
Introduction: The use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous… 
Highly Cited
2016
Highly Cited
2016
Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys
R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to esketamine (S-ketamine), since it might be… 
Highly Cited
2016
Highly Cited
2016
Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
BackgroundThe effect of intranasal esketamine on cognitive functioning in healthy participants is assessed in this study… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)